Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7715925 | 0.90 | HTR6 (0.44) | MEN1KMT2AHTR6ACHEL3MBTL1 | |
| SCHEMBL19473273 | 0.87 | MEN1 (0.42) | MEN1KMT2AHTR6ACHEL3MBTL1 | |
| SCHEMBL15902183 | 0.85 | ALDH1A1 (0.45) | MEN1KMT2AHTR6ACHEL3MBTL1 | |
| SCHEMBL29443989 | 0.85 | ACHE (0.41) | MEN1KMT2AHTR6ACHEL3MBTL1 | |
| SCHEMBL626504 | 0.85 | ACHE (0.41) | MEN1KMT2AHTR6ACHEL3MBTL1 | |
| SCHEMBL29443975 | 0.85 | ALDH1A1 (0.45) | MEN1KMT2AHTR6ACHEL3MBTL1 | |
| SCHEMBL29443970 | 0.84 | ALDH1A1 (0.58) | MEN1KMT2AHTR6ACHEL3MBTL1 | |
| SCHEMBL15902037 | 0.84 | ALDH1A1 (0.58) | MEN1KMT2AHTR6ACHEL3MBTL1 | |
| SCHEMBL15902423 | 0.82 | MEN1 (0.41) | MEN1KMT2AHTR6ACHEL3MBTL1 | |
| SCHEMBL22564665 | 0.82 | PDGFRA (0.41) | HTR6L3MBTL1USP30CCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| CN-113480537-B | Quinazolinone [2,3-a ] carboline derivative and preparation method and application thereof | 广西师范大学 | 2022-05-10 | — | — | CN | disclosed |
| WO-2021263278-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-12-30 | — | — | WO | disclosed |
| CN-113480537-A | Quinazolinone [2,3-a ] carboline derivative and preparation method and application thereof | 广西师范大学 | 2021-10-08 | — | — | CN | disclosed |
| US-20190270778-A1 | Cyclic Peptides As C5a Receptor Antagonists | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| EP-3491005-A1 | CYCLIC PEPTIDES AS C5 A RECEPTOR ANTAGONISTS | Pfizer Inc (US) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018020358-A1 | CYCLIC PEPTIDES AS C5 A RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| US-20160039796-A1 | BARETTIN AND DERIVATIVES THEREOF FOR MEDICAL USE, IN PARTICULAR FOR THE TREATMENT OF DISEASES RELATED TO OXIDATIVE STRESS OR INFLAMMATION, AND FOR PRESERVING OR WASHING ORGANS | ABC BIOSCIENCE AS (NO) | 2016-02-11 | — | — | US | disclosed |
| EP-2981251-A1 | BARETTIN AND DERIVATIVES THEREOF FOR MEDICAL USE, IN PARTICULAR FOR THE TREATMENT OF DISEASES RELATED TO OXIDATIVE STRESS OR INFLAMMATION, AND FOR PRESERVING OR WASHING ORGANS | ABC Bioscience AS (NO) | 2016-02-10 | — | — | EP | disclosed |
| WO-2014162010-A1 | BARETTIN AND DERIVATIVES THEREOF FOR MEDICAL USE, IN PARTICULAR FOR THE TREATMENT OF DISEASES RELATED TO OXIDATIVE STRESS OR INFLAMMATION, AND FOR PRESERVING OR WASHING ORGANS | ABC BIOSCIENCE AS (NO) | 2014-10-09 | — | — | WO | disclosed |
| US-7964649-B2 | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090253760-A1 | HYDRINDANE ANALOGS HAVING SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2009-10-08 | — | — | US | disclosed |
| US-20080234355-A1 | DNA METHYL TRANSFERASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234355-A1 | DNA METHYL TRANSFERASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2003081199-A2 | ANTIFOULING AGENT | INNOVENTUS PROJECT AB (SE) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003081199-A2 | ANTIFOULING AGENT | INNOVENTUS PROJECT AB (SE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253760-A1 | HYDRINDANE ANALOGS HAVING SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST ACTIVITY | S1PR1, S1PR3, S1PR2 | MEN1 2536/4885KMT2A 2642/4885HTR6 452/4885 |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | MEN1 2033/4885KMT2A 2678/4885HTR6 4613/4885 |
| US-20080234355-A1 | DNA METHYL TRANSFERASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | DNMT1, DNMT3B, DNMT3A | MEN1 3950/4885KMT2A 29/4885HTR6 3204/4885 |
| US-20160039796-A1 | BARETTIN AND DERIVATIVES THEREOF FOR MEDICAL USE, IN PARTICULAR FOR THE TREATMENT OF DISEASES RELATED TO OXIDATIVE STRESS OR INFLAMMATION, AND FOR PRESERVING OR WASHING ORGANS | TYR, CAT, MPO | MEN1 2423/4885KMT2A 2007/4885HTR6 1535/4885 |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | MEN1 3710/4885KMT2A 567/4885HTR6 3814/4885 |
| US-20190270778-A1 | Cyclic Peptides As C5a Receptor Antagonists | C3AR1, C5AR1, C5AR2 | MEN1 573/4885KMT2A 4194/4885HTR6 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.